Tactogen is a public benefit company developing a next generation of mental wellness medicines. 

Our goal is to make transformative medicines that are safer, more effective, and more accessible.

Developing IP That Provides Unique Value to Patients

Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including anxiety, depression, and stress-related disorders.

November 28, 2023

TACTOGEN'S CEO MATTHEW BAGGOTT FEATURED ON HAMILTON MORRIS PODCAST

Hamilton Morris released his podcast interview with Matthew Baggott.

November 23, 2023

PSYCHEDELIC SCIENCE '23 TALK AVAILABLE FOR REPLAY

Matthew Baggott's talk, "Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine" from Psychedelic Science 2023 is now available for replay.

September 26, 2023

TACTOGEN ANNOUNCES GRANT OF U.S. PATENT COVERING MDMA ANALOGS

Tactogen announced today that the United States Patent and Trademark Office has granted U.S. patent 11767305, covering composition of matter for novel MDMA derivatives useful for the improvement of mental health. This patent represents the first U.S. patent awarded for novel psychoactive MDMA derivatives.